T. Rowe Price Associates Portfolio holdings
T. Rowe Price Associates, Inc., founded in 1937 by Thomas Rowe Price, Jr., is a globally recognized investment management firm headquartered in Baltimore, Maryland, known for its disciplined, research-driven approach to active investing. The company manages hundreds of billions in assets, offering a wide range of mutual funds, retirement plans, and advisory services tailored to individual investors, institutions, and financial intermediaries. Emphasizing long-term growth and a conservative investment philosophy, T. Rowe Price has built a strong reputation for its equity and fixed-income funds, often focusing on fundamental analysis to identify undervalued opportunities. Still publicly traded and independent, it remains a trusted name in the industry, balancing tradition with innovation to meet evolving client needs.
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
ExxonMobil
XOM
|
+$1.76B |
| 2 |
Eli Lilly
LLY
|
+$1.4B |
| 3 |
Bank of America
BAC
|
+$1.3B |
| 4 |
Tesla
TSLA
|
+$1.19B |
| 5 |
Wells Fargo
WFC
|
+$784M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
Microsoft
MSFT
|
+$6.47B |
| 2 |
Amazon
AMZN
|
+$3.71B |
| 3 |
Yum! Brands
YUM
|
+$2.84B |
| 4 |
Salesforce
CRM
|
+$2.77B |
| 5 |
Fortive
FTV
|
+$2.41B |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Technology | 26.06% |
| 2 | Healthcare | 18.72% |
| 3 | Consumer Discretionary | 14.62% |
| 4 | Financials | 10.36% |
| 5 | Communication Services | 9.01% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
|
ISPO
2776
DELISTED
Inspirato
ISPO
| $73K | ﹤0.01% |
+1,539
| New | +$114K |
|
2777
Paysafe
PSFE
$405M
| $73K | ﹤0.01% |
4,366
+1,677
| +62% | +$37.5K |
|
|
BHIL
2778
DELISTED
Benson Hill, Inc.
BHIL
| $73K | ﹤0.01% |
759
+293
| +63% | +$32.3K |
|
2779
ADMA Biologics
ADMA
$2.11B
| $71K | ﹤0.01% |
28,843
+11,109
| +63% | +$26.7K |
|
|
BMTX
2780
DELISTED
BM Technologies, Inc.
BMTX
| $71K | ﹤0.01% |
+10,600
| New | +$65.2K |
|
|
IVC
2781
DELISTED
Invacare Corporation
IVC
| $71K | ﹤0.01% |
90,300
+26,000
| +40% | +$27.4K |
|
2782
Standard BioTools
LAB
$294M
| $68K | ﹤0.01% |
61,800
+44,100
| +249% | +$66.7K |
|
2783
Vroom Inc
VRM
$54M
| $68K | ﹤0.01% |
731
| – | – |
|
|
AIM
2784
AIM ImmunoTech
AIM
$7.17M
| $68K | ﹤0.01% |
1,158
-11
| -0.9% | -$770 |
|
2785
Offerpad Solutions
OPAD
$21.8M
| $67K | ﹤0.01% |
364
+221
| +155% | +$59.6K |
|
2786
Willamette Valley Vineyards
WVVI
$12M
| $67K | ﹤0.01% |
10,850
| – | – |
|
|
WGSWW
2787
DELISTED
GeneDx Holdings Warrant
WGSWW
| $66K | ﹤0.01% |
296,043
-1,241
| -0.4% | -$348 |
|
|
LOGC
2788
DELISTED
ContextLogic
LOGC
| $66K | ﹤0.01% |
2,970
+1,160
| +64% | +$48.1K |
|
|
BRDS
2789
DELISTED
Bird Global, Inc.
BRDS
| $66K | ﹤0.01% |
7,444
+4,869
| +189% | +$57.5K |
|
2790
Blend Labs
BLND
$367M
| $64K | ﹤0.01% |
28,663
+11,009
| +62% | +$31.2K |
|
2791
ThredUp
TDUP
$416M
| $64K | ﹤0.01% |
34,505
-3,249,970
| -99% | -$8.15M |
|
2792
XBiotech
XBIT
$71M
| $64K | ﹤0.01% |
17,600
| – | – |
|
2793
MacroGenics
MGNX
$259M
| $63K | ﹤0.01% |
18,155
-6,833
| -27% | -$26.1K |
|
|
CKPT
2794
DELISTED
Checkpoint Therapeutics
CKPT
| $62K | ﹤0.01% |
5,900
| – | – |
|
2795
Mammoth Energy Services
TUSK
$154M
| $62K | ﹤0.01% |
18,000
| – | – |
|
|
EXPR
2796
DELISTED
Express, Inc.
EXPR
| $62K | ﹤0.01% |
2,843
-2,381
| -46% | -$81.3K |
|
|
TCRR
2797
DELISTED
TCR2 Therapeutics Inc. Common Stock
TCRR
| $62K | ﹤0.01% |
34,200
| – | – |
|
2798
Neuronetics
STIM
$211M
| $61K | ﹤0.01% |
19,100
+7,600
| +66% | +$27.6K |
|
2799
Stereotaxis
STXS
$137M
| $61K | ﹤0.01% |
33,600
+15,800
| +89% | +$33.9K |
|
|
EGIO
2800
DELISTED
Edgio, Inc. Common Stock
EGIO
| $60K | ﹤0.01% |
536
+223
| +71% | +$26.4K |
|
Similar funds
T. Rowe Price Associates's Q3 2022 Portfolio in Review
As of Q3 2022, T. Rowe Price Associates held 3,114 positions worth $610B, down 23% from $791B the previous quarter. Its ten largest holdings account for 31% of the portfolio.
T. Rowe Price Associates withdrew a net $168B in Q3 2022, closing 171 positions and reducing 1,248 holdings. Its most notable exit was Alcon, an estimated $1.51B position sold in full.
By sector, the portfolio is most concentrated in Technology at 26% of assets, down from 27% a quarter earlier, followed by Healthcare and Consumer Discretionary.
Against the trend, T. Rowe Price Associates opened a new position in Corebridge Financial worth $194M.
- T. Rowe Price Associates's largest Q3 2022 buy was Corebridge Financial: 9,831,688 shares worth $194M.
- T. Rowe Price Associates added most to ExxonMobil in Q3 2022, an estimated $1.76B increase.
- T. Rowe Price Associates's biggest Q3 2022 reduction was Microsoft, cutting an estimated $6.47B.
- T. Rowe Price Associates fully exited Alcon in Q3 2022, selling an estimated $1.51B.
- T. Rowe Price Associates's ten largest holdings make up 31% of its $610B portfolio in Q3 2022.
- T. Rowe Price Associates opened 154 new positions and closed 171 in Q3 2022.
- T. Rowe Price Associates's portfolio value fell 23% quarter-over-quarter to $610B.
Based on T. Rowe Price Associates's 13F filing for Q3 2022, filed 14 Nov 2022.